Venous thromboembolism, a term referring to blood clots in the veins, is an underdiagnosed and serious, yet preventable medical condition that can cause disability and death. The good news is that DVT is preventable and treatable if discovered early. If the clot is in deep vein, it is called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism.
Heparin has been the gold standard for the treatment of VTE. According to the recent study published in New England Journal of Medicine in 2017, Rivaroxaban has been shown to be more effective in reducing the risk of recurrent events in patients with VTE. Other treatment options include intermittent pneumatic compression devices and compression stockings.
Get FREE Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/188
Increasing prevalence of venous thromboembolism across the globe is expected to boost the growth of the global venous thromboembolism (VTE) market over the forecast period. VTE is a leading cause of death and disability worldwide. For instance, as reported by the International Society on Thrombosis and Hemostasis, every year, around ten million cases of VTE occur worldwide. Moreover, according to the same source, venous thromboembolism accounts for around 100,000 to 300,000 deaths every year in the United States. Moreover, there are around 544,000 VTE related deaths reported annually in Europe. It is also estimated that 60% of VTE cases occur during or after hospitalization.
Furthermore, availability of novel drugs/treatment is expected to propel growth of the global venous thromboembolism (VTE) market. For instance, in March 2017, Apex (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) trial reported that extended use of betrixaban followed by parenteral prophylaxis with enoxaparin reduces the incidence of VTE in patients discharged from hospital. This treatment approach could significantly benefit those with venous thromboembolism.
Low public awareness is expected to boost the growth of the global venous thromboembolism (VTE) market over the forecast period, especially in emerging nations such as China, India, Turkey, Brazil, and Indonesia.
North America, Europe, and Latin America are expected to witness robust growth in the global venous thromboembolism (VTE) market, owing to the increasing prevalence of VTE in these regions. For instance, article published in 2014 by the steering committee of world Thrombosis Day, the prevalence of venous thromboembolism in the these regions was in the range of 0.75-2.69 per 1,000 individuals, which increase to 2-7 per 1,000 individuals in population aged 70 years and above.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/188
Moreover, Asia Pacific is expected to witness substantial growth in the market, owing to the increasing number clinical trials in the region. For instance, in March 2017, Daiichi Sankyo Company, Limited announced that it has commenced a company-initiated large-scale clinical registry for cancer patients (hereafter, Cancer-VTE Registry).
Key players operating in the global venous thromboembolism (VTE) market are Pfizer Inc., Sanofi S.A., Dupont Pharm Co, Abbott Laboratories, Bayer AG, Merck & Co. Inc., Upsher-Smith Laboratories, Inc., Bristol-Myers Squibb Company, 3M Health Care, and Boehringer Ingelheim GmbH, among others.
Market players are adopting various strategies, such as product launch and approvals, to expand their product portfolio and to gain competitive edge in the market. For instance, in May 2019, the Food and Drug Administration approved dalteparin sodium (FRAGMIN, Pfizer, Inc.) to reduce the recurrence of symptomatic VTE in pediatric patients 1 month of age and older.
In July 2019, Bayer AG and Johnson & Johnson’s JNJ subsidiary, Janssen Pharmaceuticals Inc., announced new results from the phase III EINSTEIN-Jr study in children with VTE, with results similar to those seen in previous studies in adults.
In June 2017, FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
𝗖𝗵𝗿𝗶𝘀𝘁𝗺𝗮𝘀 𝗦𝗮𝗹𝗲 𝗜𝘀 𝗟𝗶𝘃𝗲!
𝗕𝘂𝘆 𝗡𝗼𝘄 𝗧𝗼 𝗔𝘃𝗮𝗶𝗹 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗙𝗿𝗼𝗺 𝟮𝟱-𝟯𝟬% 𝘁𝗶𝗹𝗹 𝟯𝟭-𝗗𝗲𝗰-𝟮𝟬𝟮𝟭
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/188
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Venous Thromboembolism (VTE) Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Venous Thromboembolism (VTE) Industry Impact
Chapter 2 Global Venous Thromboembolism (VTE) Competition by Types, Applications, and Top Regions and Countries
2.1 Global Venous Thromboembolism (VTE) (Volume and Value) by Type
2.3 Global Venous Thromboembolism (VTE) (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Venous Thromboembolism (VTE) Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Venous Thromboembolism (VTE) Market Analysis
Chapter 6 East Asia Venous Thromboembolism (VTE) Market Analysis
Chapter 7 Europe Venous Thromboembolism (VTE) Market Analysis
Chapter 8 South Asia Venous Thromboembolism (VTE) Market Analysis
Chapter 9 Southeast Asia Venous Thromboembolism (VTE) Market Analysis
Chapter 10 Middle East Venous Thromboembolism (VTE) Market Analysis
Chapter 11 Africa Venous Thromboembolism (VTE) Market Analysis
Chapter 12 Oceania Venous Thromboembolism (VTE) Market Analysis
Chapter 13 South America Venous Thromboembolism (VTE) Market Analysis
Chapter 14 Company Profiles and Key Figures in Venous Thromboembolism (VTE) Business
Chapter 15 Global Venous Thromboembolism (VTE) Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027